Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 635.0 | 58 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 398.5 | 84 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 548.0 | 56 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 596.0 | 52 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 796.0 | 52 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 1112.0 | 74 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 1335.5 | 54 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 744.0 | 49 | |
N2645 | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 886.5 | 52 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 1383.0 | 48 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 1283.0 | 40 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 539.0 | 65 | |
RA2159 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 753.5 | 50 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 371.0 | 72 | |
N2645 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 462.0 | 57 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 647.0 | 69 | |
RA2708 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 861.5 | 52 | |
RA2159 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 832.0 | 68 | |
RA2159 | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 1458.0 | 49 | ||||
N2645 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 497.5 | 50 | |
N2645 | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 542.0 | 52 | ||||
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 953.0 | 45 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 975.0 | 41 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | 2 | VEGF | 457.0 | 55 | ||||
RA2159 | IKK16 | 2.0 | uM | 2 | VEGF | 601.0 | 40 |